A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants
Status:
Completed
Trial end date:
2017-07-18
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and tolerability of a single dose of ALXN1210 subcutaneous
(SC) compared to ALXN1210 intravenous (IV) in healthy participants and to determine the
absolute bioavailability of ALXN1210 SC.